Minaguchi H

No ORCID on file · 10 papers in corpus · active 1985-1998

Study types

  • article 8
  • case-report 1
  • other 1

Condition tags

  • endometriosis 10
  • endometrioma 1
article 1998
The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem.83.2.4565

To evaluate the clinical utility of recently developed biochemical markers in the assessment of bone metabolism during GnRH agonist (GnRHa) treatment, we compared five bone resorption markers [C-telopeptide (CTX) and N-telopeptide (NTX) of …

case-report 1997
Huge ovarian endometrial cyst: a case report
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/s0301-2115(97)00115-2

We are reporting a rare case of a huge ovarian endometrioma, one as large as an adult head, and the difficulty of differential diagnosis regarding this ovarian tumor.

article 1997
Prolactin secretion in endometriotic patients
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/s0301-2115(96)02649-8

ObjectiveTo clarify a significance of prolactin (PRL) for infertility in endometriosis.Study designsFor seventy endometriotic patients with or without infertility, serum PRL concentrations measured by radioimmunoassay before and 30 min afte…

article 1996
Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
Acta obstetricia et gynecologica Scandinavica ·doi:10.3109/00016349609033310

STUDY OBJECTIVE: To determine the reversibility of bone mineral density after the cessation of GnRH agonist treatment for endometriosis. DESIGN: Longitudinal trial with 6-month treatment period and 6-month follow-up. PATIENTS: 28 Japanese p…

article 1994
Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis
Fertility and Sterility ·doi:10.1016/s0015-0282(16)56873-3

ObjectiveTo examine changes in bone mineral density (BMD) of patients treated with GnRH agonist (GnRH-a) by dual-energy X-ray absorptiometry and to understand factors related to bone loss.DesignProspective controlled trial examining BMD dur…

article 1993
Antiendometrial Autoantibodies Are Generated in Patients With Endometriosis
American journal of reproductive immunology (New York, N.Y. : 1989) ·doi:10.1111/j.1600-0897.1993.tb00575.x

PROBLEM: Our aim was to investigate endometrial antigens involved in the autoimmunity of endometriosis. METHOD: We detected endometrial antigens against which autoantibodies directed with Western blotting. RESULTS: Thirteen (72.2%), 14 (77.…

other 1992
Mechanisms involved in the pituitary desensitization induced by gonadotropin-releasing hormone agonists
American Journal of Obstetrics and Gynecology ·doi:10.1016/s0002-9378(11)91676-7

OBJECTIVE: We investigated the mechanisms of desensitization induced by gonadotropin-releasing hormone agonist in the pituitary. STUDY DESIGN: Effects of gonadotropin-releasing hormone agonist on the pituitary were studied in vitro and in …

article 1986
Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.
Progress in clinical and biological research
article 1986
Round table discussion of endometriosis and its treatment.
Progress in clinical and biological research
article 1985
Danazol (an Antigonadotropin) in the Treatment of Catamenial Pneumothorax
Asia-Oceania journal of obstetrics and gynaecology ·doi:10.1111/j.1447-0756.1985.tb00051.x

Abstract Two cases of catamenial pneumothorax treated with danazol, an isoxazole derivative of 17α‐ethinyl testosterone, are reported. The first patient, a 44‐year‐old woman who had had 31 attacks of spontaneous pneumothorax at the onset of…